There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Ginkgo Bioworks Holdings Inc. (DNA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.11, or -8.15%, to $1.24. The Ginkgo Bioworks Holdings Inc. has recorded 1,176,083 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Ginkgo Bioworks Reports First Quarter 2023 Financial Results.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
This NYSE-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.35 and fluctuated between $1.4300 as its day high and $1.2700 as its day low. The current market capitalization of Ginkgo Bioworks Holdings Inc. is $2.54B. A total of 27.06 million shares were traded on the day, compared to an average of 19.01M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, DNA has seen 10 BUY and 44 SELL insider trades, representing the acquisition of 183,692 and the disposition of 2,248,545 shares. Over the last 12 months, there were 48 BUYs and 466 SELLs from insiders. Insiders purchased 32,542,767 shares during that period but sold 67,115,621.
In the most recent transaction, Kelly Jason R sold 100,000 shares of DNA for 1.19 per share on May 04. After the transaction, the insider now owns 10,694,680 company shares. In a previous transaction on May 04, Canton Barry sold 37,650 shares at 1.19 per share. DNA shares that 10% Owner owns now total 13,616,994.
Among the insiders who sold shares, Shetty Reshma P. disposed of 37,650 shares on May 04 at a per-share price of $1.19. This resulted in the insider holding 13,616,994 shares of DNA after the transaction. In another insider transaction, Kelly Jason R sold 100,000 shares at $1.17 per share on May 03. Company shares held by the insider now total 10,794,680.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for DNA in the last 3 months, the mean price target is $4.52 with high estimates of $12.00 and low estimates of $1.75. In terms of 52-week highs and lows, DNA has a high of $4.91 and a low of $1.12.
As of this writing, DNA has an earnings estimate of -$0.09 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.06 per share and a lower estimate of -$0.12. The company reported an EPS of -$0.41 in the last quarter, which was -36.70% lower than expectations of -$0.3.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $0.94, while its Total Shareholder’s Equity was $1.57B.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 4.14.